Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy

NCT05469009 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Mild Cognitive Impairment
Alzheimer Disease 1

Interventions

DRUG: Aducanumab
DEVICE: Exablate Model 4000 Type 2
DRUG: Lecanemab

Sponsor

Ali Rezai

Collaborators

[object Object]